Literature DB >> 24742810

Quantitative 7T phase imaging in premanifest Huntington disease.

A C Apple1, K L Possin2, G Satris2, E Johnson2, J M Lupo1, A Jakary1, K Wong2, D A C Kelley3, G A Kang2, S J Sha2, J H Kramer2, M D Geschwind2, S J Nelson1, C P Hess4.   

Abstract

BACKGROUND AND
PURPOSE: In vivo MR imaging and postmortem neuropathologic studies have demonstrated elevated iron concentration and atrophy within the striatum of patients with Huntington disease, implicating neuronal loss and iron accumulation in the pathogenesis of this neurodegenerative disorder. We used 7T MR imaging to determine whether quantitative phase, a measurement that reflects both iron content and tissue microstructure, is altered in subjects with premanifest Huntington disease.
MATERIALS AND METHODS: Local field shift, calculated from 7T MR phase images, was quantified in 13 subjects with premanifest Huntington disease and 13 age- and sex-matched controls. All participants underwent 3T and 7T MR imaging, including volumetric T1 and 7T gradient recalled-echo sequences. Local field shift maps were created from 7T phase data and registered to caudate ROIs automatically parcellated from the 3T T1 images. Huntington disease-specific disease burden and neurocognitive and motor evaluations were also performed and compared with local field shift.
RESULTS: Subjects with premanifest Huntington disease had smaller caudate volume and higher local field shift than controls. A significant correlation between these measurements was not detected, and prediction accuracy for disease state improved with inclusion of both variables. A positive correlation between local field shift and genetic disease burden was also found, and there was a trend toward significant correlations between local field shift and neurocognitive tests of working memory and executive function.
CONCLUSIONS: Subjects with premanifest Huntington disease exhibit differences in 7T MR imaging phase within the caudate nuclei that correlate with genetic disease burden and trend with neurocognitive assessments. Ultra-high-field MR imaging of quantitative phase may be a useful approach for monitoring neurodegeneration in premanifest Huntington disease.
© 2014 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24742810      PMCID: PMC4425411          DOI: 10.3174/ajnr.A3932

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  38 in total

1.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

2.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease.

Authors:  E H Aylward; A M Codori; A Rosenblatt; M Sherr; J Brandt; O C Stine; P E Barta; G D Pearlson; C A Ross
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

3.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

4.  MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping.

Authors:  Berkin Bilgic; Adolf Pfefferbaum; Torsten Rohlfing; Edith V Sullivan; Elfar Adalsteinsson
Journal:  Neuroimage       Date:  2011-09-08       Impact factor: 6.556

5.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat.

Authors:  H D Rosas; J Goodman; Y I Chen; B G Jenkins; D N Kennedy; N Makris; M Patti; L J Seidman; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

6.  Preparing for preventive clinical trials: the Predict-HD study.

Authors:  Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner
Journal:  Arch Neurol       Date:  2006-06

7.  A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume.

Authors:  Randy L Buckner; Denise Head; Jamie Parker; Anthony F Fotenos; Daniel Marcus; John C Morris; Abraham Z Snyder
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

8.  Biophysical mechanisms of phase contrast in gradient echo MRI.

Authors:  Xiang He; Dmitriy A Yablonskiy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-23       Impact factor: 11.205

9.  Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases.

Authors:  Kathryn E Hammond; Janine M Lupo; Duan Xu; Meredith Metcalf; Douglas A C Kelley; Daniel Pelletier; Susan M Chang; Pratik Mukherjee; Daniel B Vigneron; Sarah J Nelson
Journal:  Neuroimage       Date:  2007-11-07       Impact factor: 6.556

10.  Texture analysis of ultrahigh field T2*-weighted MR images of the brain: application to Huntington's disease.

Authors:  Nhat Trung Doan; Simon J A van den Bogaard; Eve M Dumas; Andrew G Webb; Mark A van Buchem; Raymund A C Roos; Jeroen van der Grond; Johan H C Reiber; Julien Milles
Journal:  J Magn Reson Imaging       Date:  2013-05-30       Impact factor: 4.813

View more
  6 in total

1.  Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.

Authors:  J M G van Bergen; J Hua; P G Unschuld; I A L Lim; C K Jones; R L Margolis; C A Ross; P C M van Zijl; X Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-17       Impact factor: 3.825

2.  Surface-based morphometry reveals caudate subnuclear structural damage in patients with premotor Huntington disease.

Authors:  Hosung Kim; Ji-Hoon Kim; Katherine L Possin; Joseph Winer; Michael D Geschwind; Duan Xu; Christopher P Hess
Journal:  Brain Imaging Behav       Date:  2017-10       Impact factor: 3.978

Review 3.  Neuroimaging in Dementia.

Authors:  Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2017-12-05       Impact factor: 3.420

Review 4.  Role of iron in neurodegenerative diseases.

Authors:  Kai Li; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2016-01-21       Impact factor: 3.575

5.  Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31.

Authors:  Danielle A Simmons; Brian D Mills; Robert R Butler Iii; Jason Kuan; Tyne L M McHugh; Carolyn Akers; James Zhou; Wassim Syriani; Maged Grouban; Michael Zeineh; Frank M Longo
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

6.  Neurovascular and Immuno-Imaging: From Mechanisms to Therapies. Proceedings of the Inaugural Symposium.

Authors:  Katerina Akassoglou; Dritan Agalliu; Christopher J Chang; Dimitrios Davalos; Jaime Grutzendler; Elizabeth M C Hillman; Baljit S Khakh; David Kleinfeld; Dorian B McGavern; Sarah J Nelson; Berislav V Zlokovic
Journal:  Front Neurosci       Date:  2016-02-22       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.